Expiration date: 08/2026
The composition and form of issue:
Lozenges 1 tablet contains:
antibodies to human tumor necrosis factor alpha affinity purified (introduced in the form of a water-alcohol mixture of the active form of the active substance)1 0,003 g
1 the Active form of the active substance, the active form content of not more than 10?15 ng/g of active substance
excipients: lactose MCC magnesium stearate
in a contour acheikova packing 20 PCs. in cardboard pack 1, 2 or 5 packs.
Description pharmaceutical form:
Tablets from white to almost white color, valium forms, with valium and chamfer. On the flat side with the mark affixed MATERIA MEDICA, on the other flat side ARTHROFON.
Description pharmacological action:
The drug modulates the production and functional activity of endogenous tumor necrosis factor alpha (TNF&alpha) in rheumatoid arthritis, osteoarthritis, osteochondrosis, back pain. Anti-inflammatory and analgesic action. By reducing the production of several proinflammatory cytokines, mediators of inflammation prevent progression of inflammatory tissue damage and target organ in inflammatory-degenerative diseases.
Indications:
Joint diseases, including rheumatoid arthritis, osteoarthritis (including spondylosis). During remission the drug use in the composition of monotherapy in acute — in the complex therapy with NSAIDs.
Contraindications:
Increased individual sensitivity to product components.
Side effects:
Possible reactions of individual hypersensitivity to the drug components.
Drug interactions:
The cases of incompatibility with other drugs has so far not registered. Perhaps combination with NSAIDs.
Method of application and dose:
Inside, on the day 2 table. at the reception (hold in mouth until complete dissolution not during meals). The drug should be taken twice a day, morning and evening (before and after sleep). The recommended length of treatment to 6 months.
When expressed pain syndrome in the first 2-4 weeks of therapy is recommended up to 4 times a day in the complex therapy. The improvement in the gradual transition to acceptance table 2. 2 times a day.
Overdose:
In case of accidental overdose dyspepsia caused by members of the drug fillers.
Special instructions:
3-5 days after the start of treatment may moderately expressed transient strengthening of pain or local symptoms of inflammation, requiring changes in pharmacotherapy. In some cases, in marked strengthening of pain and local signs of inflammation it is necessary to temporarily reduce the dose to 1-2 tabl. a day.
The preparation includes lactose, and therefore it is not recommended to appoint patients with congenital galactosemia, syndrome of malabsorption of glucose or galactose, or congenital lactase deficiency.
